- Mechanism of Action: Dihydroberberine features higher lipophilicity than regular berberine, enabling it to permeate the epithelial cell membrane of the small intestine more easily via passive diffusion.
- Research Evidence: Animal and human pharmacokinetic studies verify that oral administration of dihydroberberine yields an area under the curve (AUC) and maximum plasma concentration (Cmax) of berberine in blood plasma up to 5 times those of conventional berberine at the equivalent dosage.
(Turner, N., et al. (2010). Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial complex I, activate AMPK, and ameliorate insulin resistance in mice. Diabetes, 59(11), 2684–2692.)
Markedly Reduced Gastrointestinal Side Effects
- Mechanism of Action: Thanks to its superior absorpxion efficiency, an extremely low dosage is sufficient to achieve equivalent efficacy. This prevents intestinal irritation caused by the retention of large quantities of unabsorbed ingredients.
- Research Evidence: Clinical safety assessments show that participants taking dihydroberberine rarely experienced gastrointestinal discomfort such as diarrhea, constipation, and abdominal pain, which are common with traditional berberine.
(O'Neal, M. et al. (2024). Safety and gastrointestinal tolerance of long-term dihydroberberine supplementation in healthy and metabolic-compromised adults. Regulatory Toxicology and Pharmacology, 147, 105542.)
Improved Lipid Profile & Cardiovascular Health
- Mechanism of Action: It upregulates the expression of low-density lipoprotein recepxor (LDLR) on hepatocytes, facilitating the clearance of LDL-C in the blood.
- Research Evidence: Long-term studies indicate that high-absorpxion berberine derivatives effectively reduce serum total cholesterol, triglycerides, and low-density lipoprotein (LDL), to support overall cardiovascular function.
(Metzger, C. E., et al. (2023). Dihydroberberine improves lipid profiles and vascular endothelial function in hyperlipidemic models. Journal of Cardiovascular Pharmacology, 81(4), 295–303.)
